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Hepatitis B virus (HBV) reactivation during immunosuppression can lead to severe acute
hepatitis, fulminant liver failure, and death. Here, we investigated hepatitis B surface anti-
gen (HBsAg) genetic features underlying this phenomenon by analyzing 93 patients: 29
developing HBV reactivation and 64 consecutive patients with chronic HBV infection (as
control). HBsAg genetic diversity was analyzed by population-based and ultradeep
sequencing (UDS). Before HBV reactivation, 51.7% of patients were isolated hepatitis B
core antibody (anti-HBc) positive, 31.0% inactive carriers, 6.9% anti-HBc/anti-HBs (hepa-
titis B surface antibody) positive, 6.9% isolated anti-HBs positive, and 3.4% had an overt
HBV infection. Of HBV-reactivated patients, 51.7% were treated with rituximab, 34.5%
with different chemotherapeutics, and 13.8% with corticosteroids only for inflammatory
diseases. In total, 75.9% of HBV-reactivated patients (vs. 3.1% of control patients;
P< 0.001) carried HBsAg mutations localized in immune-active HBsAg regions. Of the 13
HBsAg mutations found in these patients, 8 of 13 (M103I-L109I-T118K-P120A-Y134H-
S143L-D144E-S171F) reside in a major hydrophilic loop (target of neutralizing antibodies
[Abs]); some of them are already known to hamper HBsAg recognition by humoral
response. The remaining five (C48G-V96A-L175S-G185E-V190A) are localized in class I/
II–restricted T-cell epitopes, suggesting a role in HBV escape from T-cell-mediated
responses. By UDS, these mutations occurred in HBV-reactivated patients with a median
intrapatient prevalence of 73.3% (range, 27.6%-100%) supporting their fixation in the
viral population as a predominant species. In control patients carrying such mutations,
their median intrapatient prevalence was 4.6% (range, 2.5%-11.3%; P< 0.001). Finally,
additional N-linked glycosylation (NLG) sites within the major hydrophilic loop were
found in 24.1% of HBV-reactivated patients (vs. 0% of chronic patients; P< 0.001); 5 of 7
patients carrying these sites remained HBsAg negative despite HBV reactivation. NLG can
mask immunogenic epitopes, abrogating HBsAg recognition by Abs. Conclusion: HBV
reactivation occurs in a wide variety of clinical settings requiring immune-suppressive ther-
apy, and correlates with HBsAg mutations endowed with enhanced capability to evade
immune response. This highlights the need for careful patient monitoring in all immuno-
suppressive settings at reactivation risk and of establishing a prompt therapy to prevent
HBV-related clinical complications. (HEPATOLOGY 2015;61:823-833)
Abbreviations: aa, amino acids; AASLD, American Association for the Study of Liver Diseases; Abs, antibodies; ALT, alanine aminotransferase; anti-HBc, hepa-
titis B core antibody; anti-HBe, hepatitis B envelope antibody; anti-HBs, hepatitis B surface antibody; AST, aspartate aminotransferase; cccDNA, covalently closed
circular DNA; ELISA, enzyme-linked immunosorbent assays; GRE, glucocorticoid-responsive element; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B sur-
face antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis delta virus; HIV, human immunodeficiency virus; IQR, interquartile range; LMV,
lamivudine; NLG, N-linked glycosylation; NUC, nucelos(t)ide analog; RT, reverse transcriptase; S-HBsAg, small-sized HBV surface antigen; UDPS, ultradeep pyro-
sequencing; UDS, ultradeep sequencing; WT, wild type
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epatitis B virus (HBV) reactivation is
defined as the abrupt reappearance of HBV
(serum HBV DNA >100 IU/mL) in the
serum of a person with previously resolved infection
or a marked increase of HBV replication (>2 log
increase of serum HBV DNA from baseline level) in
an immunosuppressed patient with previously stable
chronic infection (American Association for the Study
of Liver Diseases (AASLD) Emerging Trends Confer-
ence, Arlington, Virginia, March 21-22, 2013). The
potential HBV reactivation in patients with resolved
HBV infection is related to the persistence in the
nuclei of hepatocytes (after the primary infection) of
a stable HBV-DNA minichromosome named cova-
lently closed circular DNA (cccDNA). The cccDNA
serves as a template to generate all RNAs necessary
for viral replication, and its activity is controlled by
the immune system. The balance between viral repli-
cation and immune control can explain why immu-
nosuppression can increase HBV replication in
chronically infected patients and reactivate “dormant”
HBV in individuals considered as recovered.1,2 The
acute rise in serum HBV DNA can, in turn, lead to
severe acute hepatitis, synthetic dysfunction, fulmi-
nant liver failure, and death.1-3 HBV reactivation is
most commonly reported in patients receiving cancer
chemotherapy for hematological malignancies and
those receiving bone marrow or stem cell transplanta-
tion.4 Nevertheless, this event can also occur in a
wide variety of clinical settings, including patients
receiving chemotherapy for solid tumors, recipients of
solid organ transplants, and patients receiving
immune-suppressive therapy for treatment of tumors,
as well as gastrointestinal, rheumatologic, or dermato-
logical inflammatory diseases.1,2
The incidence of HBV reactivation in the immuno-
compromised host is not accurately defined owing to
the lack of large-cohort prospective studies; however,
high percentages of HBV reactivation, ranging from
24% to 88%, have been reported in different clinical
settings.1,2 A lamivudine (LMV)-based prophylaxis has
been thus far proposed to prevent HBV reactivation.5-7
Nevertheless, despite the use of LMV, a reliable risk of
HBV reactivation still persists, reaching nearly the 20%
of patients under immune-suppression status.6 Addi-
tionally, several issues remain, including the optimal
timing and treatment length as well as the follow-up
range of preventive LMV treatment.8
Anecdotic clinical case descriptions have highlighted a
high degree of genetic variability in the S gene in patients
developing HBV reactivation.9-14 The S gene is composed
of the pre-S1, pre-S2, and S region, coding for the three
forms of HBV surface glycoproteins: the small-sized HBV
surface antigen (S-HBsAg) as well as the medium- (pre-
S21S) and large-sized surface antigen (pre-S11pre-
S21S). An in-depth characterization of the extent of
genetic variability throughout the entire S gene in patients
undergoing immunosuppression-related HBV reactivation
is still missing. Understanding this point can help in the
understanding of biological processes underlying HBV
persistence and viral reactivation. This may also provide
the basis for the design of more-effective prophylaxis in
terms of potency and duration of treatment.
In light of this, our study aims at investigating, by
both population and ultradeep pyrosequencing (UDPS),
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the extent of genetic diversity and heterogeneity
throughout the entire S gene in a well-characterized
cohort of patients experiencing immunosuppression-
related HBV reactivation, as well as to investigate the
existence of viral genetic signatures underlying this
phenomenon.
Patients and Methods
Study Population. This study included 93 patients:
29 developing immunosuppression-related HBV reactiva-
tion and 64 consecutive chronically HBV-infected
patients used as a reference group, followed in different
clinical centers in Italy (“Tor Vergata” University Hospi-
tal of Rome, “S.M. Goretti Hospital” of Latina, “S.S.
Filippo e Nicola” Hospital” of Avezzano, and Second
University of Naples). Ethical approval was deemed
unnecessary because, under Italian law, biomedical
research is subjected to previous approval by ethics com-
mittees only in the hypothesis of clinical trials on medic-
inal products for clinical use (art. 6 and art. 9, leg.
Decr. 211/2003). The research was conducted on viral
DNA samples (used for clinical routine), and data previ-
ously anonymized, according to the requirements set by
Italian Data Protection Code (leg. decree 196/2003).
Patients with immunosuppression-related HBV reacti-
vation met the criteria defined by the “Emerging Trends
Conference: Reactivation of Hepatitis B” held in Arling-
ton, Virginia, on 21-22 March 2013, promoted by the
AASLD (http://www.aasld.org/LIVERLEARNING%
C2%AE/Pages/etc.aspx). Patients experienced a reap-
pearance of serum HBV DNA (>100 IU/mL) or a
marked rise of serum HBV DNA (>2 log IU/mL from
baseline level), during or after the administration of
immunosuppressive therapy. Inactive carrier patients
were defined as patients that, before HBV reactivation,
had a persistently serum HBV DNA <2,000 IU/mL,
persistently normal transaminases, and were hepatitis B
envelope antigen (HBeAg) negative and hepatitis B
envelope antibody (anti-HBe) positive.
Plasma samples were collected at the time of the
first diagnosis of HBV reactivation. Chronically HBV-
infected patients were na€ıve to anti-HBV drugs and
had no clinical evidence of cirrhosis and hepatocellular
carcinoma. No patients had a co-infection with human
immunodeficiency virus (HIV), hepatitis delta virus
(HDV), and hepatitis C virus (HCV).
Population-Based Sequencing of the Full-Length S
Gene (Pre-S1, Pre-S2, and S). The population-
based sequencing of the full-length S gene was per-
formed on plasma samples, following a home-made
protocol, as previously described, and optimized in
order to cover the pre-S1 and pre-S2 region.15 Details
are reported in text I of the Supporting Information.
UDPS. The extent of genetic heterogeneity in
the S gene coding for the S-HBsAg was also investi-
gated by UDPS (Roche 454 Junior; Roche Diagnos-
tics Corporation, Basel, Switzerland). UDPS was
restricted to 19 reactivation cases and 22 chronically
HBV-infected patients (randomly selected). The
UDPS protocol is reported on in text II of the Sup-
porting Information.
Evolutionary Divergence. The evolutionary
divergence of the full-length S sequences (pre-S1,
pre-S2, and S region), obtained by population-based
sequencing, was estimated as the extent of nucleotide
substitutions per site determined by the Tajima-Nei
model of MEGAv5, applying a gamma distribution
with shape parameter = 1.0. The estimate variance
was assessed from the bootstrap method with shape
parameter = 1,000, and the test was conducted for
nucleotide alignment. Evolutionary divergence was
calculated for the pre-S1, pre-S2, and S region and in
the functional domains of the S-HBsAg: N-terminal
region (amino acids [aa] 1-98); major hydrophilic
region (aa 99-169), and membrane-embedded C-ter-
minus (aa 170-226).
Analysis of the N-Linked Glycosylation Sites. N-
linked glycosylation (NLG) analysis was performed on
the full-length S-HBsAg aa sequences included in the
study using the program N-Glycosite (available at:
http://www.hiv.lanl.gov/). An NLG site is identified in
the aa sequence by the motif NXS/T. Thus, the NLG
sequon has to begin with an asparagine (N) followed
by any aa except Proline. The next aa residue has to
be either a threonine (T) or a serine (S).
Mutation Prevalence. The full-length S sequences
obtained by population-based sequencing were used
to assess the association of specific mutations with
HBV reactivation. Only mutations present in >3
HBV-reactivated patients were considered for the anal-
ysis. In particular, the prevalence of each mutation
was calculated in the group of HBV-reactivated
patients and in the group of chronically HBV-infected
patients. Fisher’s exact test was performed to verify
whether the differences in frequency among the two
groups of patients were statistically significant. In
order to support their correlation with HBV reactiva-
tion, a multivariable logistic regression was performed.
The following variables were considered: patients’ age;
serum HBV DNA; alanine aminotransferase (ALT)
and aspartate aminotransferase (AST); and presence
of at least one mutation associated with HBV
reactivation.
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Sequences obtained by UDPS were used to define the
intrapatient prevalence of mutations associated with HBV
reactivation and of mutations that are known to affect S-
HBsAg recognition by antibodies (Abs) whose list is avail-
able at the following website: http://hbv.bioinf.mpi-
inf.mpg.de/index.php (updated October 2013).
Statistical Analysis. Data were analyzed using the
statistical software package SPSS (v17.0; SPSS Inc.,
Chicago, IL).
Impact of NLG Sites on HBsAg Quantification.
In order to investigate the ability of the NLG sites iden-
tified in this study on HBsAg recognition and quantifi-
cation, a plasmid encoding the HBsAg linked to a
streptavidin tag (strep-tag) was used to transfect HepG2
cells. The amount of strep-tagged HBsAg released in
culture supernatants was then quantified using different
enzyme-linked immunosorbent assays (ELISAs): a specif-
ically designed ELISA capable of recognizing the Strep-
tag linked to the HBsAg (defined as Strep-tag-based
ELISA) and two ELISAs directed against the HBsAg
protein (Architect [Abbott, Abbott Park, IL] and Mono-
lisa [Bio-Rad, Hercules, CA]). Two independent experi-
ments were carried out, each in duplicate. Details are
reported in text III of the Supporting Information.
Results
Patients’ Characteristics. This study included 29
patients developing immunosuppression-related HBV
reactivation (Table 1). Most patients were male
(65.5%) with a median (interquartile range; IQR) age
of 63 (61-72) years. At the diagnosis of HBV reactiva-
tion, median (IQR) serum HBV DNA was 6.1 (4.1-
8.0) log IU/mL and median (IQR) of ALT and AST
were 315 (35-552) and 91 (29-267) IU/L, respectively.
Median duration of immunosuppression was 15 (9-45)
months. Regarding the serological status of HBV infection
before viral reactivation, 51.7% (15 of 29) of patients
were isolated hepatitis B core antibody (anti-HBc) posi-
tive, 31.0% (9 of 29) were inactive carriers, 6.9% (2 of
29) were anti-HBc and hepatitis B surface antibody (anti-
HBs) positive, 6.9% (2 of 29) were isolated anti-HBs pos-
itive, and 3.4% (1 of 29) had an overt HBV infection.
Before immunosuppression, patients negative for HBsAg
and positive for anti-HBc had serum HBV DNA <20
IU/mL, and inactive carriers had serum HBV DNA rang-
ing from 20 to 441 IU/mL. The patient with overt HBV
infection had serum HBV DNA of 51,896 IU/mL. A
total of 51.7% of HBV-reactivated patients were treated
with rituximab for hematologic malignancies and 34.5%
were treated with other immunosuppressive drugs (includ-
ing fludarabine, everolimus1mycophenolate, methotrex-
ate, and vincristine1dexamethasone) for different
neoplasias; of interest, the remaining patients (13.8%)
underwent a therapy only based on corticosteroids for
autoimmune or inflammatory diseases, such as chronic
Table 1. Patients’ Characteristics
Patients’ Characteristics
HBV-Reactivated
Patients*
(N = 29)
Chronically
Infected
Patients*†
(N = 64)
Male, N (%) 19 (65.5) 43 (68.3)
Italian nationality, N (%) 29 (100) 48 (80)
Median age, Yyars (IQR) 63 (61-72) 51 (39-65)
Median HBV DNA, log IU/mL (IQR) 6.1 (4.1-8.0)‡ 4.7 (3.2-6.2)
Median ALT, IU/L (IQR) 315 (35-568)‡ 49 (31-102)
Median AST, IU/L (IQR) 91 (29-267)‡ 40 (25-71)
HBV genotype D, N (%) 29 (90.6) 64 (100)
Prereactivation HBV status, N (%)
Isolated anti-HBc positive 15 (51.7) —
Anti-HBc positive/anti-HBs positive 2 (6.9) —
Inactive carrier§ 9 (31.0) —
Isolated anti-HBs positive 2 (6.9) —
Active carrier 1 (3.4) —
Median duration of
immunosuppression (IQR)k
15 (9-45)
Immunosoppressive therapy, N (%)
Rituximab-containing chemotherapy 15 (51.7) —
Corticosteroids alone 4 (13.8) —
Other chemotherapies¶ 10 (34.5) —
Immune-suppressive therapy
at HBV reactivation, N (%)
Ongoing 13 (44.8) —
Concluded 14 (48.3) —
Unknown 2 (6.9) —
Pathology requiring
immune-suppressive
therapy, N (%)
Non-Hodgkin lymphoma/
other lymphomas
13 (44.8) —
Chronic lymphoid leukemia/acute
myeloid leukemia
6 (20.7) —
Chronic inflammatory diseases# 4 (13.8) —
Multiple myeloma 2 (6.9) —
Kidney transplantation 3 (10,3) —
Other cancers 1 (3.4) —
LMV prophylaxis, N (%) 9 (31.0) —
Outcome
Acute hepatitis B phase resolution 16 (55.2) —
Chronicization of HBV infection 1 (3.4) —
Death 7 (24.1) —
Unknown 1 (3.4) —
*No patients were coinfected with HIV, HCV, and HDV.
†Chronically HBV-infected patients were consecutively collected. They were
na€ıve to anti-HBV drugs without evidence of end-stage liver disease.
‡At the time of diagnosis of HBV reactivation.
§Inactive carriers were defined as patients that, before HBV reactivation, had
a serum HBV DNA <2,000 IU/ml, persistently normal transaminases, and were
HBeAg negative and anti-HBe positive.
kDatum available for 22 of 29 patients.
¶Other chemotherapies included the following treatments: fludarabine; evero-
limus1mycophenolate; methotrexate; and vincristine1dexamethasone.
#Chronic inflammatory diseases include: chronic obstructive pulmonary dis-
ease; nodose panarteritis; and psoriasis-related arthritis.
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obstructive pulmonary disease, panarteritis nodosa, and
psoriatic arthritis.
Notably, in 48.3% of patients, HBV reactivation
occurred after discontinuation of immunosuppressive
therapy (range, 1-14 months). Patients developing HBV
reactivation after discontinuation of immunosuppression
were significantly older than patients developing HBV
reactivation during immunosuppression (67 [63-75] vs.
60 [52-66] years; P = 0.034; Supporting Table 1). Con-
versely, a negative correlation was observed between the
use of corticosteroids for chronic inflammatory diseases
and HBV reactivation after completing immunosuppres-
sion (30.8% vs. 0%; P = 0.025; Supporting Table 1).
No other correlations were found.
Overall, 24.1% of patients (7 of 29) died within 6
months after HBV reactivation: 4 for liver failure and
3 for progression of the underlying pathology requir-
ing immunosuppressive therapy.
Drug Resistance in Patients With HBV Reactiva-
tion Despite LMV Prophylaxis. In our study, 9
patients developed HBV reactivation despite LMV pro-
phylaxis (median [IQR] duration: 12 [11-29] months).
The primary LMV resistance mutations, rtM204V or
rtM204I, were detected in 3 patients at reactivation.
rtM204V was detected in 2 patients along with other
mutations (rtL180M, rtV173L, and rtA181S), whereas
rtM204I was present alone in a single patient. As a
result of the overlapping between the RT and S-HBsAg
gene, rtM204V corresponded to sI195M in S-HBsAg
in both patients, rtM204I to sI196L, rtV173L to
sE164D, and rtA181S to sW172C.
In a single patient, rtQ215S, potentially affecting
LMV efficacy, was found. Mutations associated with
alkyl-phosphonate resistance (rtA181T/V, rtN236T,
and rtA194T) were not detected.
Genetic Determinants in the Full-Length S Gene
Underlying Immunosuppression-Related HBV Reac-
tivation In Vivo. The extent of genetic diversity in
pre-S1, pre-S2, and S-HBsAg underlying
immunosuppression-related HBV reactivation was
investigated. A group of 64 consecutive, nonselected,
chronically HBV D-genotype-infected patients was
used as a reference group. These patients had a median
(IQR) serum HBV DNA of 4.7 (3.2-6.2) log IU/mL
and median ALT and AST of 49 (31-102) and 40 IU/
mL (25-71), respectively (Table 1). All of them were
na€ıve to any anti-HBV drug treatment.
The mean evolutionary divergence of S-HBsAg
sequences was significantly higher in patients with
HBV reactivation than in chronically infected patients
(mean evolutionary divergence: 0.017 [1 0.005] vs.
0.009 [1 0.004]; P< 0.001). The highest mean evolu-
tionary divergence was observed in the major hydro-
philic region, target of neutralizing Abs (mean
evolutionary divergence: 0.032 [6 0.012] vs. 0.018
[6 0.009], P 0.001). The mean S-HBsAg evolution-
ary divergence did not correlate with the duration of
immunosuppression (rho = 20.14; P = 0.54).
Differently from HBsAg, no differences in mean
evolutionary divergence were observed in the pre-S1
and pre-S2 region (0.025 [6 0.009] vs. 0.032 [6
0.010], P = 0.4 for pre-S1; 0.032 [6 0.015] vs. 0.032
[6 0.015], P = 0.4 for pre-S2).
The above-mentioned results prompted us to inves-
tigate the existence of specific genetic elements in S-
HBsAg specifying immunosuppression-related HBV
reactivation.
Overall, 13 S-HBsAg-mutations were significantly
correlated with immunosuppression-related HBV
reactivation (Fig. 1A; P values from <0.001 to 0.03).
Twenty-two of twenty-four (75.9%) patients with
HBV reactivation (vs. only 2 of 64 chronically
infected patients) carried more than one of these
mutations.
Conversely, in our cohort of 64 chronically infected
patients, such mutations were completely absent (0 of
64 for sC48G, sV96A, sM103I, sL109I, sT118K,
sT120A, sY134H, sS143L, sD144E, sS171F, sL175S,
sG185E, and sV190A) or nearly absent (only 1 of 64
for sT118K and sL175S). Their prevalence ranged
from 10.3% to 20.7% in patients with HBV reactiva-
tion, compared to 0%-1.6% in the 64 chronically
infected patients. By multivariable analysis, the pres-
ence of at least one of these S-HBsAg mutations was
independently correlated with immunosuppression-
related HBV reactivation therapy after correction for
patient age, serum HBV DNA, and ALT and AST
(91.04 [14.10-586.30]; P< 0.001; Table 2).
Beyond these specific mutations, five additional S-
HBsAg positions (100, 114, 115, 145, and 154) were
found mutated more frequently in patients with HBV
reactivation than in chronically infected patients (Fig.
1B). Prevalence of these mutated positions ranged
from 10.3% to 20.7% in patients with HBV reactiva-
tion, compared to 0%-3.1% in the 64 chronically
infected patients (P< 0.05).
No mutations in the pre-S1 and pre-S2 region were
correlated with HBV reactivation status.
Localization of S-HBsAg Residues Correlated
With Immunosuppression-Related HBV Reactiva-
tion. Of the 13 S-HBsAg mutations associated with
HBV reactivation, 7 of 13 (sM103I, sL109I, sT118K,
sP120A, sY134H, sS143L, and sD144E) reside in a
major hydrophilic loop (aa: 99-169), the main B-cell
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epitope of HBV. Among them, sT118K, sP120A,
sY134H, sS143L, and sD144E are already known to
hamper S-HBsAg recognition by Abs (http://
hbv.bioinf.mpi-inf.mpg.de/index.php). The remaining
five mutations (sC48G, sV96A, sS171F, sL175S,
sG185E, and sV190A) are localized in T-cell epitopes
belonging to class I (sC48G, sV96A, sL175S, and
sG185E) or II (sS171F).16 All the five positions (100,
114, 115, 145, and 154), found mutated more often
in HBV-reactivated patients than in chronically
infected patients, reside in the major hydrophilic
region of the S-HBsAg.
Furthermore, among the 13 S-HBsAg mutations
identified, seven correspond to mutations in reverse
transcriptase (RT): sC48G (rtV56G); sM103I
(rtV112I/L); sL109I (rtS117Y); sT118K (rtH126Q);
sP120A (rtT128G/S); sY134H (rtV142A); and
sV190A (rtL199V). Among them, only rtL199V local-
ized close to the catalytically active YMDD motif
encompassing the RT positions 203-206.
Data From UDPS: Intrapatient Distribution of
Mutations Associated With HBV Reactivation.
UDPS analysis was led in 19 HBV-reactivated
patients and 22 chronically infected patients. In
Fig. 1. Histogram reports the 13 S-
HBsAg mutations whose prevelance
was significantly higher in HBV-
reactivated patients than in chronically
infected patients (CHB patients; used
as a reference group) (A), the five S-
HBsAg positions found mutated more
significantly in HBV-reactivated patients
than in CHB patients (B), and the per-
centage of patients with at least one
additional glycosylation site in the
major hydrophilic region (C). Statisti-
cally significant differences were
assessed by Fisher’s exact test. This
analysis was led in 29 HBV-reactivated
patients and 64 chronically infected
patients all infected with HBV genotype
D. *P< 0.05; **P< 0.01;
***P< 0.001. In (A) and (B), black
and dark gray bars indicate the per-
centage of HBV-reactivated patients in
which the S-HBsAg mutations were
detected as pure mutation and as a
mixture, respectively. White and light
gray bars indicate the percentage of
CHB patients in which the S-HBsAg
mutations were detected as pure
mutation and as a mixture, respec-
tively. In (C), black and white bars
indicate the percentage of HBV-
reactivated patients with at least one
additional NLG site in HBsAg. No addi-
tional NLG sites were detected in
patients with chronic HBV infection.
Abbreviation: CHB, chronic hepatitis B.
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HBV-reactivated patients, no statistically significant
differences in demographic and clinical characteristics
were found after stratification for UDPS availability
(Supporting Table 2). Similarly, prevalence of the S-
HBsAg-mutations associated with HBV reactivation
was comparable between the group of HBV-
reactivated patients with UDPS and that without
UDPS.
In the reference group, all the demographic and
clinical characteristics (with the exception of serum
HBV DNA) were comparable (Supporting Table 2).
By UDPS, S-HBsAg mutations associated with
HBV-reactivation occurred in 13 of 19 of HBV-
reactivated patients with a median (IQR) intrapatient
prevalence of 73.3% (27.6%-100%; Fig. 2A). Con-
versely, in chronically infected patients, the median
(IQR) intrapatient prevalence of S-HBsAg mutations
associated with HBV reactivation showed a remarkable
decrease (4.6% [2.5%-11.3%]; P = 0.007). In 2
chronically infected patients, these mutations occurred
with an intrapatient prevalence of 46.6% and 28.4%,
respectively, and in 5 patients they occurred as minor-
ity species with an intrapatient prevalence from 0.7%
to 11.3% (thus not detectable by the standard
sequencing methodology; Fig. 2B).
A similar scenario was found analyzing mutations
known to hamper HBsAg recognition by Abs (defined
as immune-escape mutations; for their list, please cite
http://hbv.bioinf.mpi-inf.mpg.de/index.php). Indeed,
the median (IQR) intrapatient prevalence of these
mutations was 55.8%(29.7%-97.9%) in HBV-
reactivated patients and 6.8% (3.4%-79.7%) in
chronically infected patients (P = 0.03).
An Enrichment of Genotypically Defined S-HBsAg
NLG Sites Characterizes HBV Reactivation. By
analyzing the S-HBsAg sequences, additional NLG
sites in the major hydrophilic region were found in
24.1% (7 of 29) of patients with HBV reactivation,
whereas they were completely absent in chronically
infected patients (P< 0.001; Fig. 1C).
In 5 patients, a single additional NLG site was
detected resulting from the point mutations, sT115N
and sT123N, in 2 patients each, respectively, and from
the insertion of an N between the S-HBsAg positions,
114 and 115, in the remaining patient (ins115N).
Notably, 2 additional glycosylation sites were detected
in 2 patients, resulting from the point mutations,
sS113N1sT131N, in the former and from the muta-
tion, sT117N, combined with the insertion of an N
between the S-HBsAg positions, 113 and 114
(ins114N), in the latter.
Notwithstanding, among the 7 patients with addi-
tional glycosylation sites, 5 were isolated anti-HBc pos-
itive (before HBV reactivation) and remained HBsAg
negative despite HBV reactivation.
N-Glycosylation Impact on HBsAg Quantifica-
tion. The plasmid encoding the strep-tagged HBsAg,
carrying the wild-type (WT) sequence or the above-
mentioned NLG sites, were used to transfect HepG2
cells. The amount of strep-tagged HBsAg released in
supernatants was then quantified using the ELISAs
described in the Materials and Methods section. The
additional NLG site resulting from the mutation,
K160N, and known to affect HBsAg recognition was
used as a control.
By using the ELISA targeting the strep-tag linked to
the HBsAg, the additional NLG sites did not affect
the quantification of the strep-tagged HBsAg, which
was comparable to that observed for the WT (Fig. 3).
Conversely, all the NLG sites (except the pattern,
S113N1T131N) determined a drastic reduction in
the quantification of the strep-tagged HBsAg when the
Architect and Bio-Rad assays (both targeting the
HBsAg) were used (Fig. 3). This decrease was >90%
Table 2. Odds Ratio for the Association of S-HBsAg Mutations With Immunosuppression-Related HBV Reactivation From
Fitting a Multivariable Logistic Regression Model
Variables
Univariable Analysis* Multivariable Analysis*
Odds Ratio P Value Odds Ratio P Value
Age (per 1-year increase) 1.10 (1.04-1.14) <0.001 1.08 (1.00-1.17) 0.048
HBV DNA (per 1log IU/mL increase) 1.42 (1.10-1.83) 0.006 1.62 (0.94-2.79) 0.082
ALT (per 20-IU/mL increase) 1.10 (1.04-1.17) 0.001 1.12 (1.01-1.23) 0.027
AST (per 20-IU/ml increase) 1.06 (0.99-1.12) 0.091 — —
At least 1 mutation associated with HBV reactivation† 97.43 (18.81-504.79) <0.001 91.04 (14.10-586.3) <0.001
*The analysis was performed on 93 patients infected by HBV of genotype D. For this analysis, the following variables were considered: age, ALT/AST values and
the presence of at least one S-HBsAg mutation significantly correlated with immunosuppression-driven HBV reactivation. All variables with a P < 0.01 at univari-
able analysis were included in the multivariable analysis. Statistically significant P values in the multivariate analysis are in bold.
†The 13 S-HBsAg mutations associated with immunosuppression-driven HBV reactivation (Fig. 1A) were considered in this analysis.
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(compared to WT) for four of five glycosylation sites
analyzed (98.5% for T115N, 94.1% for ins115N,
92% for T123N, and 90.2% for T117N1ins114N)
by using the Bio-Rad assay and for three of five glyco-
sylation sites (99.9% for T115N, 94.7% for ins115N,
and 99.4% for T123N) by using the Architect assay
(Fig. 3). These results show that the NLG sites identi-
fied in this study hamper HBsAg recognition and
quantification without affecting HBsAg release.
Discussion
This study highlights a high degree of genetic com-
plexity in the S-HBsAg sequences isolated from
patients with immunosuppression-related HBV reacti-
vation. It also provides a snapshot from real clinical
practice on the clinical characteristics of HBV-
reactivated patients. To our knowledge, this is one of
the first European studies addressing this point in a
relatively large cohort of patients.
We show that immunosuppression-related HBV reacti-
vation can occur in a large variety of anti-HBV serological
profiles. In particular, in our study, a large fraction
(51.7%) of HBV-reactivated patients were isolated anti-
HBc positive and 6.9% were anti-HBc and anti-HBs posi-
tive. The high prevalence of isolated anti-HBc-positive
patients supports the notion that an undetectable anti-
HBs level at the starting of immunosuppressive therapy
correlates with an increased risk of HBV reactivation (Seto
W, Chan T, Hwang Y, Choi O, Wong D, Fung J, et al.
Interim analysis of hepatitis B reactivation in patients with
prior HBV exposure undergoing hematopoietic stem cell
transplant. The Liver Meeting for AASLD, 2013. Abstract
#34). Moreover, 41.2% of anti-HBc-positive patients (1
anti-HBs) were receiving an immunosuppressive therapy
not including rituximab or anti–tumor necrosis factor
agents. This group of patients (thus far considered at low
risk of HBV reactivation1) may thus require further atten-
tion and investigation, particularly in term of establishing
ab initio an effective prophylaxis.
Thus far, little information is available on HBV
reactivation in patients receiving corticosteroids alone.
In our study, 13.8% (4 of 29) of patients developed
HBV reactivation during treatment with corticosteroids
for autoimmune or chronic inflammatory diseases.
Among them, 2 were isolated anti-HBc positive and 2
were inactive carriers. Thus, patients undergoing ther-
apy based only on corticosteroids is another category
of patients requiring more attention in terms of
screening and/or monitoring of HBV markers during
immunosuppressive therapy.
Of note, in our study, HBV reactivation after discon-
tinuation of immunosuppressive therapy was observed in
48.3% of patients and was positively correlated with
patients’ age. Such a correlation can be explained by the
fact that older patients require more time to reconstitute
the immune system. Thus, after discontinuation of
immunosuppressive therapy, the status of immunosup-
pression can persist longer, predisposing the patients to
HBVreactivation for a prolonged time.
Conversely, HBV reactivation after discontinuing
immunosuppression was negatively correlated with use
Fig. 2. Graph reports the intrapatient prevalence of S-HBsAg-mutations
for each patient in the HBV-reactivated group (N = 19) (A) and in the group
of chronically infected patients used as a reference (N = 22) (B). Intrapa-
tient prevalence was expressed as percent of reads with the specific muta-
tion. The relative dimension of black and gray dots represents the
intrapatient prevalence of S-HBsAg mutations correlated with HBV reactiva-
tion and of S-HBsAg mutations known as immune-escape mutations,
respectively. The list of S-HBsAg mutations associated with an altered S-
HBsAg recognition by Abs is reported in http://hbv.bioinf.mpi-inf.mpg.de/
index.php. The gray area includes mutations with an intrapatient prevalence
<20% defined as minority species not detected by standard population-
based sequencing. Abbreviation: CHB, chronic hepatitis B.
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of corticosteroids. This can be explained by the fact
that the HBV genome contains a glucocorticoid-
responsive element (GRE) whose stimulation enhances
the rate of cccDNA transcription and, in turn, HBV
replication.17 In this light, it is conceivable that inter-
ruption of corticosteroids can shut down GRE stimu-
lation, thus repressing cccDNA transcriptional activity.
No information is thus far available on mechanisms
underlying immunosuppression-related HBV reactiva-
tion in patients with “resolved” or inactive HBV infec-
tion. In this study, by analyzing the full-length S gene
(pre-S1, pre-S2, and S-HBsAg), we found an unex-
pectedly high degree of genetic diversity and complex-
ity in S-HBsAg from patients with HBV reactivation.
We also identified 13 S-HBsAg genetic signatures in
immune-active S-HBsAg regions significantly corre-
lated with the status of HBV reactivation. The major-
ity of them reside in the major hydrophilic region;
some of them are already known to act as immune-
escape mutations. Among them, the mutations
sY134H, sS143L, and sD144E reside in a particularly
immunogenic segment encompassing the aa 139-
149.18 sD144E has been implicated in immune escape
and/or diminished affinity for monoclonal Abs.19 This
mutation has been also described in a case of
corticosteroid-induced reactivation of latent HBV
infection in an HIV-positive patient.12 Within the
139-149 segment, we also observed an enrichment of
variability at the S-HBsAg position 145, known to
abrogate the production of, as well as reduce the
HBsAg affinity for, neutralizing Abs.16,20 Mutations at
position 145 as well as at positions 100, 109, 118,
134, 144, and 154 have been also detected during
HBV reactivation in previous studies (based on clinical
case description or lower number of patients).9-14 The
slight discrepancies in the patterns of S-HBsAg muta-
tions reported in our and other studies can be mainly
ascribed to the inclusion of different HBV genotypes.
However, we cannot exclude that other factors, such as
the type of immunosuppressive regimen, and serologi-
cal status of HBV infection before reactivation, can
influence the patterns of mutations detected during
HBV reactivation.
To further corroborate the association of these
mutations with HBV reactivation, their prevalence was
also evaluated in two distinct groups of patients (all
with HBV genotype D): the former composed by 44
acutely infected patients and the latter composed by
148 nucelos(t)ide analog (NUC)-treated chronically
infected patients.15 The association of the 13 HBsAg
mutations with HBV reactivation was fully confirmed
in these two data sets (P values ranging from 0.01 to
0.002 in acutely infected patients and from 0.01 to
0.004 in NUC-treated patients). In acutely infected
patients, none of the 13 HBsAg-mutations associated
with HBV reactivation were detected by population
sequencing. Similarly, in NUC-treated patients, 8 of
13 HBsAg mutations were never detected and the
remaining five occurred with a prevalence <1.5%.
This range of prevalence is superimposable to that
observed in drug-na€ıve patients (0%-1.6%).
By UDPS, the S-HBsAg-mutations associated with
HBV reactivation status mainly occur as predominant
species with a high intrapatient prevalence, suggesting
their ability to confer a selective advantage. Con-
versely, in chronically infected patients, these muta-
tions (if detected) mainly occur as minority species.
We cannot establish whether these mutations are gen-
erated or have been selected from archived cccDNA
during immunosuppressive therapy. However, the
clustering of these mutations in S-HBsAg immune-
active regions suggests that the suboptimal immune
response during the initial weakening of the immune
system can determine a remodulation of viral quasi-
species structure leading to a shift toward highly
mutated viral species endowed with enhanced poten-
tial to evade immune response. From an evolutionary
point of view, the high degree of S-HBsAg genetic
Fig. 3. Quantification of strep-tagged HBsAg released in supernatants of HepG2 cell cultures by different ELISAs are shown. For each mutant,
the amount of strep-tagged HBsAg released in supernatants was expressed as a percentage, considering the amount of the WT strep-tagged
HBsAg as 100%. The mutant, K160N, was used as a control. Results represent the mean values (6 standard deviation) of two experiments,
each in duplicate. Dotted line indicates a 90% inhibition in HBsAg recongition and quantification.
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variability observed in HBV-reactivated patients is in
agreement with the theory known as “the survival of
the flattest.” This theory postulates that, under high
mutation rates, the evolution does not necessarily
favor the single viral variant with the faster replica-
tion capacity, but a more robust cloud of viral var-
iants, interconnected by mutations, whose average
replication rate is the highest.21 Thus, the selection of
multiple variants becomes the best way to counteract
changes in the environment.
We also highlighted, in 24.1% of HBV-reactivated
patients, an enrichment of additional NLG sites, in
the major hydrophilic region of the S-HBsAg, not
occurring in chronically infected patients. By using
an ELISA capable of recognizing a strep-tag linked to
the HBsAg, we found that, in the presence of NLG
sites, the amount of strep-tagged HBsAg measured by
the classical ELISA is drastically or totally abrogated,
whereas the amount of strep-tagged HBsAg measured
by the Strep-tag based ELISA is comparable to that
observed for the WT strep-tagged HBsAg. These
results support that the NLG sites identified in this
study hamper HBsAg recognition and quantification
without affecting HBsAg release. NLG sites play a
critical role in viral evasion from humoral responses.
Indeed, they can mask B-cell epitope and thus pro-
tein surface target of neutralizing Abs. The additional
NLG sites observed in HBV-reactivated patients
derived from complex mutational events, and the
majority of them were HBsAg negative despite reacti-
vation of viral replication. This corroborates the abil-
ity of these NLG sites to interfere with S-HBsAg
recognition by Abs by masking B-cell epitope. This is
in line with a recent study showing that S-HBsAg
mutants with new N-glycosylation sites reacted
weakly with anti-HBs. Native gel analysis of secreted
virion in supernatants of transfected HuH7 cells indi-
cated that mutants had better virion enveloping and
secretion capacity than WT HBV.22 This suggests
that, beyond acting as immune-escape mutations,
these additional NLG sites may also provide an
advantage in terms of replicative capacity. In vitro
experiments are necessary in order to verify the
impact of these sites on the glycosylation process and
HBV replication capacity
In our study, 9 patients developed HBV reactivation
despite LMV prophylaxis. Most of them (6 of 9) did not
develop rtM204I/V. It is known that pharmacological
pressure cooperates with immunological pressure in sup-
pressing HBV replication.23 In the setting of immune
suppression and abundant presence of S-HBsAg
immune-escape mutations, the low-potent LMV may
fail to prevent HBV recurrence. In this regard, a recent
study showed a high efficacy of entecavir in preventing
HBV reactivation in patients with patients with lym-
phoma and resolved HBV infection.24
In conclusion, HBV reactivation correlates with a
complex quasi-species carrying HBsAg mutations in
immune-active regions and with the presence addi-
tional NLG sites that can contribute to HBV escape
by neutralizing and diagnostic Abs. This underlines
the importance of a careful patient monitoring in all
immunosuppressive settings at reactivation risk, a
proper assessment of the best time of onset and dura-
tion of prophylaxis, and the prompt introduction of a
potent therapy in order to prevent HBV-related clini-
cal complications.
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